SCHEMBL5652799

SCHEMBL5652799

CCN(CC)CCCNC(=O)c1ccc(-c2nc3c(C)c(C)c(Br)cc3[nH]2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GLA P06280 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 3/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
MAPT P10636 2/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
TSHR P16473 1/20 0.39
HDAC4 P56524 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5649826 0.92 GAA (0.43) GAAKDM4EGLAHSD17B10TP53
SCHEMBL5648656 0.91 GAA (0.42) GAAKDM4EGLAHSD17B10TP53
SCHEMBL5651519 0.88 FLT3 (0.45) KDM4EHSD17B10
SCHEMBL5653201 0.88 PRMT5 (0.48) GAAKDM4EGLAHSD17B10TP53
SCHEMBL5652439 0.87 HPSE (0.44) GAAKDM4EGLAHSD17B10TP53
SCHEMBL5652552 0.87 HDAC6 (0.44) GAAKDM4EGLAHSD17B10TP53
SCHEMBL5652790 0.86 GAA (0.43) GAAKDM4EGLAHSD17B10TP53
SCHEMBL5651790 0.81 TSHR (0.52) TSHRALDH1A1KMT2A
SCHEMBL5653317 0.81 FLT3 (0.46) KDM4EHSD17B10
SCHEMBL5653019 0.81 METAP2 (0.46) GAAKDM4EGLAHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 GAA 4139/4885KDM4E 1605/4885GLA 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.